Skip to content

Adductor Canal Block for Total Knee Arthroplasty

Impact of Volume of Local Anesthetic Injected for Adductor Canal Block on Recovery Profile and Block Characteristics Following Total Knee Arthroplasty.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02453360
Enrollment
60
Registered
2015-05-25
Start date
2015-05-31
Completion date
2017-07-31
Last updated
2019-08-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthroplasty, Replacement, Knee, Pain, Postoperative

Keywords

Anesthesia, Analgesia

Brief summary

Total knee arthroplasty (TKA) can be associated with a large amount of postoperative pain. This pain can oftentimes be severe enough to limit participation in physical therapy and ultimately delay discharge resulting in increased cost. Several strategies have been developed in an effort to decrease postoperative pain following TKA while maintaining lower extremity strength and maximizing participation in physical therapy. Recently, adductor canal blockade has gained popularity as it is reported to provide analgesia to the anterior knee without resulting in significant quadriceps muscle weakness. However, few studies have carefully evaluated the impact of volume of injection of local anesthetic into the adductor canal on motor weakness or pain control. The ability to achieve similar pain control with decreased volumes of local anesthetic would allow the surgery team to apply more local anesthetic to posterior knee structures. Decreased volumes of local anesthetic may also be associated with a decreased risk of local anesthetic toxicity. This study aims to carefully evaluate this relationship using a physical therapy evaluation method that relies on both motor strength and pain control. In addition, the investigators hope to carefully evaluate motor strength using a novel method of strength measurement in an effort to further evaluate the impact of volume of injection of local anesthetic into the adductor canal on motor strength.

Detailed description

Postoperative analgesia for total knee arthroplasty (TKA) is incredibly important as it allows for effective physical therapy and ultimately ensures proper function of the implanted joint hardware. Unfortunately, TKA is oftentimes associated with pain severe enough to limit participation in physical therapy which can ultimately result in prolonged hospitalizations and perhaps decreased joint function. A number of strategies have been reported to decrease the pain associated with TKA. Opioids are commonly utilized but they can be associated with a number of potential side effects including nausea, itching, respiratory depression, tolerance and the potential for abuse. Epidural analgesia has been utilized for postoperative analgesia but this strategy requires urinary catheterization (potential source of increased incidence of urinary tract infections), causes significant vasodilation with resulting hypotension and can cause bilateral lower extremity weakness that can undermine efforts at early physical therapy and rehabilitation. Femoral nerve blockade and femoral nerve catheters have the potential to decrease pain in the anterior knee but use of this technique is limited by incomplete analgesia and quadriceps motor weakness. Some groups have advocated for the substitution or addition of sciatic or obturator nerve blocks to femoral nerve blockade but this is at the expense of increased lower extremity weakness and little potential clinical benefit.1-5 In an effort to balance the need for effective postoperative analgesia with the need to maintain lower extremity muscle strength for active participation in physical therapy, a number of groups have begun to evaluate the adductor canal block. The adductor canal is located in the middle 1/3 of the thigh and includes the saphenous nerve and nerve to the vastus medialis. The primary advantage to adductor canal blockade versus femoral nerve blockade is a potential sparing of the nerves to the quadriceps muscle and therefore preservation of lower extremity motor strength.6-8 Kwofie et al reported in a study of 16 volunteers that there was no change in quadriceps strength or hip adduction following the injection of 15 ml of local anesthetic. This is interesting as the obturator nerve is reported to travel within the adductor canal and is responsible for hip adduction. Kwofie et al also reported that SSACNB resulted in significantly decreased impairments with balance compared to a SSFNB.9 To this point, the majority of studies evaluating adductor canal blockade have focused on continuous techniques and little has been done to evaluate single shot techniques. Continuous techniques have the potential to extend analgesia but this is at the expense of increased cost, effort, resource utilization and potentially increased risk of infection. The safety of CACNB technique was highlighted by a study by Henningsen et al where no cases of nerve injury related to analgesic technique were reported in a series of 97 patients.10 Andersen et al compared a CACNB vs control in 40 patients and found that the intervention group reported decreased pain and sleep disturbances while retaining the ability to ambulate soon after surgery.11 Mudumbai et al evaluated 180 patients undergoing TKA and discovered that continuous adductor canal nerve blockade (CACNB) relative to continuous femoral nerve blockade (CFNB) resulted in greater ability to ambulate (37 m vs 6 m) on POD 1 and similar pain scores.8 Jaeger et al examined a similar group of 54 patients presenting for TKA and found that CACNB relative to CFNB resulted in decreased quadriceps weakness and no difference in pain, opioid consumption or weakness.12 Jenstrup et al reported that, compared to placebo, CACNB resulted in decreased pain with flexion and opioid consumption.13 Only recently has a study comparing SSACNB and SSFNB been published. This study demonstrated that SSACNB resulted in decreased postoperative quadriceps weakness and similar pain control to SSFNB.14 Of interest, previous research has demonstrated that 15 ml 0.5% ropivacaine is required to produce ultrasound guided femoral nerve blockade (including sensory and quadriceps motor weakness) but no such study has yet been done for the adductor canal block.15 It is possible that larger volumes of local anesthetic injected into the adductor canal could result in proximal spread of local anesthetic and increase quadriceps weakness and difficulty ambulating. It is also possible that decreased volumes of injection may result in inferior pain control and difficulties participating in physical therapy.

Interventions

PROCEDUREAdductor Canal Block

Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.

Sponsors

University of Wisconsin, Madison
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. The subject is scheduled for elective unilateral TKA 2. The subject is ≥ 18 years and ≤ 80 years; 3. The subject's weight is between 70-120 kg; and 4. The subject's primary anesthesia care team has planned for a neuraxial anesthetic (i.e. spinal, epidural or combined-spinal epidural). 5. The patient agrees to receive an adductor canal block. 6. American Society of Anesthesiologists class 1-3

Exclusion criteria

1. Subject is \< 18 years of age or \>80 years of age; 2. Subject is non-English speaking; 3. Subject is known or believed to be pregnant; 4. Subject is a prisoner; 5. Subject has impaired decision-making capacity; per discretion of the Investigator 6. Symptomatic untreated gastroesophageal reflux or otherwise at risk for perioperative aspiration; 7. Any condition for which the primary anesthesia care team deems neuraxial anesthesia inappropriate; 8. Significant pre-existing neuropathy on the operative limb; 9. Significant renal, cardiac or hepatic disease per discretion of the investigator. 10. American Society of Anesthesiologists class 4-5 11. Known hypersensitivity and/or allergies to local anesthetics 12. Chronic Opioid Use (daily or almost daily use of opioids for \> 3 months)

Design outcomes

Primary

MeasureTime frameDescription
10 Meter Walk Test24 hours postoperatively following total knee arthroplastyThis will be evaluated by determining how quickly a patient is able to ambulate over 10 meters on POD 1 (10 meter walk test).

Secondary

MeasureTime frameDescription
Opioid ConsumptionPACU Discharge through 24 hours postoperativelyOpioid Requirements will be retrieved from the patient's electronic medical record
Pain With Activity at 24 Hours24 Hours Following SurgeryPatient pain will be assessed by having participants describe pain using Numerical Ranking Scale (NRS) with a total score of 0-10 where 0 is no pain and 10 is the worst pain imaginable. Location of pain will also be assessed.
Percentage Change in Knee Extension Strength From Baseline24 Hours Following SurgeryPatient strength will be assessed by asking subjects to maximally adduct their leg or extend their knee for five seconds. Subjects will be asked to repeat this measurement three times at each measurement (pre-block, 15 minutes post-block, 24 hours post-block and 48 hours post-block). Strength measurements will be made with the Kiio strength monitoring device.
Number of Participants With Nausea at 24 HoursPerioperative through 48 hours postoperativelyNeed for antiemetic therapy will be assessed through evaluation of the electronic medical record.

Countries

United States

Participant flow

Participants by arm

ArmCount
5 ml
Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB. Adductor Canal Block: Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.
20
10 ml
Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB. Adductor Canal Block: Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.
20
20 ml
Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB. Adductor Canal Block: Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.
20
Total60

Baseline characteristics

Characteristic5 ml10 ml20 mlTotal
Age, Continuous64.6 years
STANDARD_DEVIATION 6.9
62.6 years
STANDARD_DEVIATION 7.8
62 years
STANDARD_DEVIATION 7.6
63.1 years
STANDARD_DEVIATION 7.4
ASA Physical Status Classification System Score2 units on a scale2 units on a scale2 units on a scale2 units on a scale
Body Mass Index kg/m231.1 kg/m^2
STANDARD_DEVIATION 3.8
34.3 kg/m^2
STANDARD_DEVIATION 6
34.2 kg/m^2
STANDARD_DEVIATION 5.9
33.2 kg/m^2
STANDARD_DEVIATION 5.5
Race and Ethnicity Not Collected0 Participants
Region of Enrollment
United States
20 participants20 participants20 participants60 participants
Sex: Female, Male
Female
10 Participants15 Participants14 Participants39 Participants
Sex: Female, Male
Male
10 Participants5 Participants6 Participants21 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 200 / 200 / 20
other
Total, other adverse events
0 / 200 / 200 / 20
serious
Total, serious adverse events
0 / 200 / 200 / 20

Outcome results

Primary

10 Meter Walk Test

This will be evaluated by determining how quickly a patient is able to ambulate over 10 meters on POD 1 (10 meter walk test).

Time frame: 24 hours postoperatively following total knee arthroplasty

Population: Incomplete data responsible for discrepancies between number of subjects enrolled and data reported.

ArmMeasureValue (MEAN)Dispersion
5 ml10 Meter Walk Test38.6 SecondsStandard Deviation 33.3
10 ml10 Meter Walk Test49.8 SecondsStandard Deviation 55.4
20 ml10 Meter Walk Test43.3 SecondsStandard Deviation 31.5
Secondary

Number of Participants With Nausea at 24 Hours

Need for antiemetic therapy will be assessed through evaluation of the electronic medical record.

Time frame: Perioperative through 48 hours postoperatively

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
5 mlNumber of Participants With Nausea at 24 Hours11 Participants
10 mlNumber of Participants With Nausea at 24 Hours11 Participants
20 mlNumber of Participants With Nausea at 24 Hours6 Participants
Secondary

Opioid Consumption

Opioid Requirements will be retrieved from the patient's electronic medical record

Time frame: PACU Discharge through 24 hours postoperatively

ArmMeasureValue (MEAN)Dispersion
5 mlOpioid Consumption33.8 Morphine Equivalents (mg)Standard Deviation 20.5
10 mlOpioid Consumption30.9 Morphine Equivalents (mg)Standard Deviation 16.2
20 mlOpioid Consumption29.1 Morphine Equivalents (mg)Standard Deviation 14.6
Secondary

Pain With Activity at 24 Hours

Patient pain will be assessed by having participants describe pain using Numerical Ranking Scale (NRS) with a total score of 0-10 where 0 is no pain and 10 is the worst pain imaginable. Location of pain will also be assessed.

Time frame: 24 Hours Following Surgery

Population: Incomplete data responsible for discrepancies between number of subjects enrolled and data reported.

ArmMeasureValue (MEAN)Dispersion
5 mlPain With Activity at 24 Hours5 Scores on a scaleStandard Deviation 2
10 mlPain With Activity at 24 Hours5 Scores on a scaleStandard Deviation 2
20 mlPain With Activity at 24 Hours6 Scores on a scaleStandard Deviation 1.9
Secondary

Percentage Change in Knee Extension Strength From Baseline

Patient strength will be assessed by asking subjects to maximally adduct their leg or extend their knee for five seconds. Subjects will be asked to repeat this measurement three times at each measurement (pre-block, 15 minutes post-block, 24 hours post-block and 48 hours post-block). Strength measurements will be made with the Kiio strength monitoring device.

Time frame: 24 Hours Following Surgery

Population: Incomplete data responsible for discrepancies between number of subjects enrolled and data reported.

ArmMeasureValue (MEAN)Dispersion
5 mlPercentage Change in Knee Extension Strength From Baseline-59.7 percentage change of Baseline StrengthStandard Deviation 28.1
10 mlPercentage Change in Knee Extension Strength From Baseline-55 percentage change of Baseline StrengthStandard Deviation 24
20 mlPercentage Change in Knee Extension Strength From Baseline-64.3 percentage change of Baseline StrengthStandard Deviation 21.4

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026